StockData
Vistagen Therapeutics, Inc. logo

Vistagen Therapeutics, Inc. (VTGN) stock

VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3076% below fair value
$0.20+0.01 (+6.12%)

Close on Nov 18, 2026Market cap $8.85MP/E –Yield –

Vistagen Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Vistagen Therapeutics's free cash flow for the twelve months ending Mar 31, 2023 was -$50.24M. For fiscal 2024 it was -$25.81M. The highest annual figure on record is -$4.83M in fiscal 2016.

Annual free cash flow

PeriodPeriod endValueChange
FY2024Mar 31, 2024-$25.81M–
FY2023Mar 31, 2023-$50.24M–
FY2022Mar 31, 2022-$45.26M–
FY2021Mar 31, 2021-$12.35M–
FY2020Mar 31, 2020-$15.76M–
FY2019Mar 31, 2019-$14.70M–
FY2018Mar 31, 2018-$9.06M–
FY2017Mar 31, 2017-$7.50M–
FY2016Mar 31, 2016-$4.83M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2023CQ1 2023Mar 31, 2023-$7.79M–
Q3 FY2023CQ4 2022Dec 31, 2022-$9.95M–
Q2 FY2023CQ3 2022Sep 30, 2022-$16.37M–
Q1 FY2023CQ2 2022Jun 30, 2022-$16.14M–
Q4 FY2022CQ1 2022Mar 31, 2022-$15.39M–
Q3 FY2022CQ4 2021Dec 31, 2021-$12.05M–
Q2 FY2022CQ3 2021Sep 30, 2021-$11.50M–
Q1 FY2022CQ2 2021Jun 30, 2021-$6.32M–
Q4 FY2021CQ1 2021Mar 31, 2021-$5.31M–
Q1 FY2021CQ2 2020Jun 30, 2020-$2.81M–
Q4 FY2019CQ1 2019Mar 31, 2019-$3.73M–
Q3 FY2019CQ4 2018Dec 31, 2018-$3.91M–
Q4 FY2018CQ1 2018Mar 31, 2018-$2.60M–
Q3 FY2018CQ4 2017Dec 31, 2017-$2.45M–

More Vistagen Therapeutics figures

See a number that looks wrong?